Evidence map›Paper›PMID 34067686›Full record

ArticleMicroorganisms2021

Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer.

Juris Jansons, Dace Skrastina, Alisa Kurlanda, Stefan Petkov, Darya Avdoshina, Yulia Kuzmenko, Olga Krotova, Olga Trofimova, Ilya Gordeychuk, Irina Sominskaya and 1 more

Open access · goldAbstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Juris JansonsInstitute of Microbiology and Virology, Riga Stradins University, LV-1007 Riga, Latvia.ORCID 0000-0003-0845-4392
Dace SkrastinaLatvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia.
Alisa KurlandaInstitute of Microbiology and Virology, Riga Stradins University, LV-1007 Riga, Latvia.
Stefan PetkovDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden.ORCID 0000-0002-8052-9646
Darya AvdoshinaChumakov Federal Scientific Center for Research and Development of Immune-and Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.ORCID 0000-0001-8168-5969
Yulia KuzmenkoEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Olga KrotovaDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 17177 Stockholm, Sweden.
Olga TrofimovaInstitute of Microbiology and Virology, Riga Stradins University, LV-1007 Riga, Latvia.
Ilya GordeychukChumakov Federal Scientific Center for Research and Development of Immune-and Biological Products of Russian Academy of Sciences, 108819 Moscow, Russia.
Irina SominskayaLatvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia.ORCID 0000-0002-1932-369X
Maria IsaguliantsInstitute of Microbiology and Virology, Riga Stradins University, LV-1007 Riga, Latvia.ORCID 0000-0001-9382-2254
Latvian Biomedical Research and Study Centre · LVRussian Academy of Sciences · RUKarolinska Institutet · SEEngelhardt Institute of Molecular Biology · RU

Funding

Karolinska Institutet FoBe 2018-02329Latvijas Zinātnes Padome LZP-2018/2-0308Latvijas Zinātnes Padome LZP-2020/2-0376
6 · The paper itself

Abstract

Chronic HCV infection and associated liver cancer impose a heavy burden on the healthcare system. Direct acting antivirals eliminate HCV, unless it is drug resistant, and partially reverse liver disease, but they cannot cure HCV-related cancer. A possible remedy could be a multi-component immunotherapeutic vaccine targeting both HCV-infected and malignant cells, but also those not infected with HCV. To meet this need we developed a two-component DNA vaccine based on the highly conserved core protein of HCV to target HCV-infected cells, and a renowned tumor-associated antigen telomerase reverse transcriptase (TERT) based on the rat TERT, to target malignant cells. Their synthetic genes were expression-optimized, and HCV core was truncated after aa 152 (Core152opt) to delete the domain interfering with immunogenicity. Core152opt and TERT DNA were highly immunogenic in BALB/c mice, inducing IFN-γ/IL-2/TNF-α response of CD4+ and CD8+ T cells. Additionally, DNA-immunization with TERT enhanced cellular immune response against luciferase encoded by a co-delivered plasmid (Luc DNA). However, DNA-immunization with Core152opt and TERT mix resulted in abrogation of immune response against both components. A loss of bioluminescence signal after co-delivery of TERT and Luc DNA into mice indicated that TERT affects the in vivo expression of luciferase directed by the immediate early cytomegalovirus and interferon-β promoters. Panel of mutant TERT variants was created and tested for their expression effects. TERT with deleted N-terminal nucleoli localization signal and mutations abrogating telomerase activity still suppressed the IFN-β driven Luc expression, while the inactivated reverse transcriptase domain of TERT and its analogue, enzymatically active HIV-1 reverse transcriptase, exerted only weak suppressive effects, implying that suppression relied on the presence of the full-length/nearly full-length TERT, but not its enzymatic activity. The effect(s) could be due to interference of the ectopically expressed xenogeneic rat TERT with biogenesis of mRNA, ribosomes and protein translation in murine cells, affecting the expression of immunogens. HCV core can aggravate this effect, leading to early apoptosis of co-expressing cells, preventing the induction of immune response.

Indexed as

assays of reporter expressionCD4+ and CD8+ T cell responseeukaryotic expressionhepatitis C virushepatocellular carcinomaimmune suppressionimmunotherapyinduction of type I interferonsmulti-component DNA vaccinenucleocapsid (core) proteintelomerase reverse transcriptase

Identifiers

PMID34067686
PMCPMC8156932
OpenAlexW3162705980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.